Community banks rarely make headlines, but their dividends can command loyal followings, and Auburn National Bancorporation is a case in point. The Alabama-basedHolding Companybehind AuburnBank pays a steady quarterly cash dividend that, against a share price in the mid-$20s, produces a yield of roughly …
The ownership figure is based on 75,256,381 Health Catalyst (NASDAQ: HCAT) shares outstanding as of July 31, 2026.
Utility stocks rarely make headlines, but their dividends do the talking, and Avista Corporation has been talking to income investors for a long time. The Spokane-based electric andNatural GasUtilityserves customers across eastern Washington, northern Idaho and parts of Oregon.
Inhibrx Biosciences, Inc. (NASDAQ: INBX) reported a 48.3% confirmed objective response rate for INBRX-106 plus pembrolizumab in a randomized Phase 2 HNSCC study. Pembrolizumab alone produced a 26.5% response rate, giving the combination the higher result in the primary endpoint analysis.
Baker Boyer Bancorp is not a household name, but among income investors who hunt for durable community-bank payouts it has earned a following. TheHolding Companyfor Baker Boyer National Bank in Walla Walla, Washington, pays a quarterly dividend that, against its share price, produces a …
InnovAge Holding Corp. (NASDAQ: INNV) set fiscal 2027 revenue guidance at $1,050 million to $1,085 million, with Adjusted EBITDA projected between $105 million and $115 million. The company also expects census of 8,625 to 8,850 participants and total member months of 101,000 to 102,500. …
Jakarta Clinic Construction and Subscription Structure
BCB Bancorp, the New Jersey-based parent of BCB Community Bank, shows up on income screens with a trailingDividend Yieldabove 5%.
Brookfield Renewable Corporation has become a familiar name for investors who want exposure to wind, hydro, solar and storageAssetswithout giving up a meaningful cash return. With the shares recently near $32.56 and a trailing yield in the high-4% range, the stock is once again …
Intellia Therapeutics, Inc. (NASDAQ: NTLA) has secured FDA acceptance and Priority Review for itsBiologicslicense application for lonvoguran ziclumeran, or lonvo-z. The application is supported by trial data showing an 87% reduction in mean monthly hereditary angioedema attacks versus placebo. The FDA set March 10, …